SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) — ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), is pleased to announce the findings from a randomized contralateral eye study comparing patient outcomes and preferences for a combination therapy with individual eye drop medications after ocular surgery. The prospective study was conducted at a single site where patients underwent cataract surgery with both eyes and each eye was randomly selected for the test and control group. Subjects were evaluated at day 1, 15 and 30 measuring visual acuities, refraction, intraocular pressure, macular thickness, patient pain and overall patient satisfaction. According to the study, the ImprimisRx combination drop showed similar health outcomes to multiple separately dosed drops, and that the combination drop was unanimously preferred by patients as it was easier to manage.
The results of the study were recently published in Clinical Ophthalmology, Volume 14, 2020, a peer-reviewed journal focused on the clinical advancements in ophthalmology. The study followed 33 patients who underwent cataract surgery and received the combination drop (prednisolone acetate 1%, gatifloxacin 0.5%, and bromfenac sodium 0.075%) in one randomly selected eye, while the other eye received the same individual eye drop medications post-surgery.It was noted by the investigator, “Enrollment for this study was relatively slow, as it was difficult to find eligible patients willing to use the three different drops instead of the combination drop; the latter is the standard of care in our clinic.”John Saharek, President of ImprimisRx, commented, “Post ocular surgery, patients are usually required to instill multiple topical drops to prevent infection, inflammation, and pain, often with a different bottle used for each drop. For some patients this can be confusing and/or can be burdensome, which could lead to non-compliance and suboptimal health outcomes. ImprimisRx formulations such as LessDrops® provide the unique ability to combine these individual ingredients into one bottle.”The full study can be found on the Dovepress website or by clicking here.About ImprimisRx’s LessDrops® Combination DropsAll LessDrops® formulations are made in ImprimisRx’s FDA-registered outsourcing facility and are compounded according to the highest federal pharmaceutical production standards. To learn more about ImprimisRx’s ophthalmic formulations, please visit our website by clicking here.About ImprimisRxImprimisRx is the nation’s leading ophthalmology-focused outsourcing facility and pharmaceutical compounding business, serving thousands of ophthalmologists and optometrists in all 50 states, with 40 proprietary ophthalmic formulations. ImprimisRx is headquartered in San Diego, CA and owns two FDA-inspected production and dispensing facilities in Ledgewood, New Jersey. There have been over one million eyes served by the formulations produced at these facilities. For more information about ImprimisRx, including ordering instructions, please visit our website, www.imprimisrx.com.About Harrow HealthHarrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including ImprimisRx, the nation’s leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, and Melt Pharmaceuticals. Harrow also owns Mayfield Pharmaceuticals, Stowe Pharmaceuticals, and Visionology, all companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain drug candidates being developed by Surface, Melt, and Mayfield. Harrow intends to create, invest in and grow paradigm shifting healthcare businesses that put patients first. For more information about Harrow Health, please visit the Investor Relations section of the corporate website by clicking here.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; physician interest in prescribing our formulations; risks related to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Harrow Health’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC’s web site at www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow Health undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.No ImprimisRx compounded formulation is FDA-approved. Other than drugs compounded at a registered outsourcing facility, all ImprimisRx compounded formulations require a prescription for an individually identified patient consistent with federal and state laws.Media Contact:
Deb Holliday
Holliday Communications, Inc.
[email protected]
412.877.4519Investor Contact:
Jon Patton
[email protected]
858-704-4587Source: Harrow Health, Inc.
Bay Street News
